If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
9.10    0.00 (0.00%)
Bid:
8.70
Ask:
9.50
Spread: 0.80 (9.195%)
Market Cap: £19.93m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Holding(s) in Company

26 Sep 2012 07:00

RNS Number : 1412N
Phytopharm PLC
26 September 2012
 



TR-1: notification of major interests in shares

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Phytopharm plc

 

2. Reason for the notification  (please tick the appropriate box or boxes)

 

An acquisition or disposal of voting rights

X

 

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An event changing the breakdown of voting rights

 

Other (please specify): Placing and a change in the ISC

 

3. Full name of person(s) subject to the notification obligation:

Henderson Global Investors

 

4. Full name of shareholder(s) (if different from 3.):

 

5. Date of the transaction (and date on which the threshold is crossed or reached if different)

24 September 2012

 

6. Date on which issuer notified:

25 September 2012

 

7. Threshold(s) that is/are crossed or reached:

12%

 

 

 

 

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type of shares

 if possible using the ISIN CODE

Situation previous to the Triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Direct x

Indirect xi

Direct

Indirect

Ordinary 1 Pence

GB0006869720

 

38,247,242

 

38,247,242

 

 

 

41,697,242

 

12.02%

 

B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/ Conversion Period/ Date

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

 

Total (A+B)

Number of voting rights

% of voting rights

41,697,242

12.02%

 

 

 

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

Notification using the total voting rights figure of 346,801,972

14. Contact name:

Zoe McGowan, Company Secretary

15. Contact telephone number:

01480 437697

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEELFLLKFEBBE
Date   Source Headline
7th Jul 20267:00 amRNSTrading Update
19th Jun 20267:00 amRNSExercise of Options
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.